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Abstract
Background
Rapid access to evidence is crucial in times of an evolving clinical crisis. To that end, we propose a novel
approach to answer clinical queries, termed rapid meta-analysis (RMA). Unlike traditional meta-analysis,
RMA balances a quick time to production with reasonable data quality assurances, leveraging artificial
intelligence (AI) to strike this balance.
Objective
We aimed to evaluate whether RMA can generate meaningful clinical insights, but crucially, in a much
faster processing time than traditional meta-analysis, using a relevant, real-world example.
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Methods
The development of our RMA approach was motivated by a currently relevant clinical question: is ocular
toxicity and vision compromise a side effect of hydroxychloroquine therapy? At the time of designing this
study, hydroxychloroquine was a leading candidate in the treatment of coronavirus disease (COVID-19).
We then leveraged AI to pull and screen articles, automatically extract their results, review the studies, and
analyze the data with standard statistical methods.
Results
By combining AI with human analysis in our RMA, we generated a meaningful, clinical result in less than
30 minutes. The RMA identified 11 studies considering ocular toxicity as a side effect of
hydroxychloroquine and estimated the incidence to be 3.4% (95% CI 1.11%-9.96%). The heterogeneity
across individual study findings was high, which should be taken into account in interpretation of the result.
Conclusions
We demonstrate that a novel approach to meta-analysis using AI can generate meaningful clinical insights
in a much shorter time period than traditional meta-analysis.
Keywords: meta-analysis, rapid meta-analysis, artificial intelligence, drug, analysis, hydroxychloroquine,
toxic, COVID-19, treatment, side effect, ocular, eye
Introduction
The capacity of artificial intelligence (AI) to aggregate and process massive volumes of information is
emerging as particularly crucial in the current moment, especially as the large amount of data available can
be overwhelming for humans to evaluate [1]. AI technology can alleviate the burden of some of this
overload by automatically processing the written text of medical papers, and converting the text into a more
consumable, structured set of data that can be easily searched and analyzed. Essentially, AI turns all of the
written articles into spreadsheets of results.
Further, although meta-analysis and systematic literature review are the gold standards for evidence [2],
these analyses require significant time and effort to produce (often as long as 1 year [3]) and are therefore
rarely updated [4,5].
Therefore, to produce this evidence in a more timely manner, we here propose the rapid meta-analysis
(RMA). An RMA follows the same general framework methodology of a traditional meta-analysis, but
leverages technology at each step, yielding a much faster time to production. Some data quality may be
compromised due to the emphasis on fast time to production, but the ability to generate answers so quickly
may warrant this tradeoff.
We were motivated to develop the RMA method based on a practical example of the current need for
obtaining a rapid consensus on evidence from the literature. Hydroxychloroquine has been available since
the 1950s [6] and has been used to treat malaria, lupus erythematosus, and rheumatoid arthritis. Most
recently, hydroxychloroquine has been highlighted as a potential intervention to support patients with
coronavirus disease (COVID-19). Although the efficacy outcomes of hydroxychloroquine are different in
each clinical condition for which it is used, adverse events tend to be consistent. In this study, we used
RMA to answer a specific clinical question regarding hydroxychloroquine and the degree to which ocular
toxicity is a side effect. This is an important clinical question; however, we were not able to find a suitable
aggregation of results.
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The core innovation of an RMA is replacing as many of the steps of manual meta-analysis as possible with
machine intelligence, as has been proposed previously [4,7]. Machines are not yet at the point where they
can simply provide an answer to a posed question; therefore, RMA instead replaces as many manual steps
as possible with machine assistance (or entirely AI). The goal is that each step could eventually be replaced
with AI.
Figure 1 provides a schematic to make this idea more concrete. The left of the figure shows the standard
steps (at a high level) for meta-analysis and the right side shows the equivalent steps with technology
replacement.
For this RMA, we leveraged the Evid Science clinical outcomes database [8] for searching and screening
(although any suitable AI system could provide a similar benefit). This database was built using the Evid
Science AI, which is capable of turning written text of results into a “structured” representation (eg, a row
in a database or spreadsheet).
Figure 2 shows a sentence from an article about toxicity detected for a set of patients, which has been
parsed by the Evid Science AI. The AI was able to break this sentence down into fields (such as result,
intervention, and outcome) automatically. In particular, it knows that 18 is the number of patients, and since
that represents 30.5% of the patients, it must be 18 of 59. It also knows that 18 was associated with
“Retinal toxicity being detected” in contrast to 5, which is associated with “color vision impairments.”
Previous AI-related approaches have attempted to identify sentences associated with Patient/Problem,
Intervention, Comparison, Outcome (PICO) parameters from studies [9,10], surface more relevant articles
for screening [11], and even study characteristics, including bias [12]. However, we were not able to find
another AI that was purposely built to parse the full, numeric results from the text directly (eg, numbers and
their associated fields), which are the inputs required for an advanced investigation such as a meta-analysis.
To train the AI to perform this task, researchers at Evid Science employed supervised machine learning. In
this methodology, the researchers initially gave the system very explicit examples of the type of output they
wanted; similar to the format shown in Figure 2, these comprised sets of sentences and the associated
structured results.
The machine was then trained with a dataset of thousands of such examples from a wide variety of articles
in the literature. The learning process enables the machine to produce these types of output for brand new
sentences. To be clear, the articles chosen for training were selected from multiple disease topics and with
various interventions, and were not only focused on hydroxychloroquine. As the system improves, it can
even be taught to correct mistakes, rather than having to start with fresh examples each time, thereby
limiting the effort involved in refining its learning.
Methods
Evid Science AI
The Evid Science AI is a deep-learning model, written in python, constructed from layers of transformers
and bidirectional long-short term memory (bi-LSTM) units. Our model first encodes the inputs using the
transformer language model (SciBERT [13]), which turns the words into a mathematical space where
similar words are grouped together. These embedded inputs are then passed along through the bi-LSTM
layers of the network, which traverse words in the text and labels them appropriately. We trained our
algorithm on 24,614 labeled records.
Model Performance
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Recently, we performed a dual-annotator analysis of extraction accuracy. One hundred results were
randomly selected from the database, each of which contains a result record (eg, numerator, denominator,
percent, measurement value, unit, intervention/study group, outcome) and a sentence. Of note, a single
sentence can be associated with multiple results; however, in randomizing, we chose one result to label for
accuracy. Further, not all sentences have values for all fields. We then labeled the extracted fields
(numerator, denominator, percent, measurement value, unit, intervention/study group, outcome) for
accuracy. Our labels are provided as a spreadsheet in Multimedia Appendix 1.
The labels could be “perfect” (eg, a field was perfectly extracted); “near perfect” (eg, the field contained
extra words or missed a few words, but was otherwise understandable, such as an outcome of “attained
remission” contains the extra word “attained”); or “incorrect.” We also included “missing” as a means for
estimating recall (true recall is hard to measure, given that we would require full labeling of all documents).
The 100 sentences and labels are shown in Multimedia Appendix 1.
Specifically, for each field, we report the estimated recall, precision (which is accuracy), perfect precision
(accuracy only considering perfect extractions), and F-measure (harmonic mean between recall and
precision).
Using the Model for RMA
From a practical perspective, in previous work, we demonstrated a similar process to RMA using the Evid
Science AI to replicate the results from a systematic literature review [14]. Crucially, by leveraging AI, we
produced the results in 6 days rather than the months it took to produce the original. In addition, given the
time between the original publication and AI-assisted version, 22 new relevant results had been published.
Of note, the current version of the AI used for this RMA is significantly more powerful than the version
previously used for systematic literature review replication.
The Evid Science clinical outcomes database used in this RMA is the result of running the AI over the
entirety of the publicly (freely) available medical literature (PubMed). The current database has nearly
70,000,000 “facts” associated with results from articles, which users can search and screen through.
The Evid Science platform has already indexed the entirety of PubMed, and each night, it pulls in the latest
papers. The architecture for the system is shown in Figure 3. Starting at the left, articles come into the
system via the PubMed application programming interface (API). Machine-learning classifiers are then
applied to articles, determining the study type (eg, trial, observational study) and other methodology
information. The extraction algorithm described above is then applied to the article. Each result from the
extraction algorithm is then stored in our database and users can retrieve these results via searching and
filtering via a web-based user interface. Final results can be exported (in CSV format) so that they can be
analyzed in sophisticated statistical programs such as R.
Therefore, our RMA proceeds by searching and screening through this database, as described below. The
search itself (Step 1) leverages PubMed APIs, and therefore returns equivalent articles to PubMed. That is,
any search on our platform is passed to the PubMed API, and the returned articles are then matched against
what our AI has extracted. Therefore, the initial search results are equivalent.
Screening is then simplified, since the AI has processed the text into structured records that can be filtered
and screened efficiently. For instance, we can simply filter results associated with “toxicity” in the outcome
(or other outcomes of interest). This is more efficient than manually reading each returned abstract, since
one only screens articles in the filtered set.
After searching and screening, a user obtains the final dataset for analysis (which the AI helped to produce
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via extraction). One can perform many analyses directly within the Evid Science web-based tool or export
data to Excel and then analyze it with other programs (as we have done).
Results
RMA Process for the Association of Eye Issues With Hydroxychloroquine Use
We initially performed a search for hydroxychloroquine on the Evid Science platform, and filtered down to
results in which the outcome was major vision impairments (eg, “maculopathy,” “blind,” “toxicity”). In this
study, we focused solely on PubMed abstracts, since they are freely available. This yielded 22 candidate
articles from a possible set of 5010 articles related to hydroxychloroquine, 1352 of which were identified as
primary studies (eg, clinical trial or observational study) by our AI and were therefore included as possible
articles to process results from.
After screening, we were left with 11 papers for our RMA; the other 11 excluded articles were published
before 2000 or focused on the diagnosis of ocular issues. The search took less than 1 minute and the
screening took 22 minutes. Most of the work involved selecting the papers and lightly cleaning the results
to make the table of results easier to read. Two results required “more significant” human intervention: one
result was reported as having “all cases” of documented blindness attributed to causes other than
hydroxychloroquine, and we therefore needed to invert this result to be 0 cases attributed to
hydroxychloroquine; the other result had a misattributed denominator, which was manually fixed. All other
changes involved removing single words, which was required very infrequently in concordance with the
accuracy results shown in Table 1.
The results from the search and screening processes are shown in Table 2, which served as the input for our
meta-analysis computation. Although we did not conduct the equivalent screening manually, in previous
work, we were able to use our AI to match a published systematic literature review on inflammatory bowel
disease [14], and therefore have already demonstrated that we can generate the equivalent screening using
our tool to that obtained with a manual process.
RMA Outcome
We then performed a meta-analysis of the results from the screened out articles using a generalized linear
mixed model (in R), as these are binary occurrences of having an eye issue. We chose a random-effects
model for the analysis, demonstrating a result of 3.4 events of eye issues per 100 observations (95% CI
1.11-9.96). The code for this analysis was already written; therefore, plugging in the data (Table 2) and
running it took roughly 2 minutes, including exporting the data to Excel, renaming and selecting columns
to conform to R code input, and running the code.
The forest plot of the meta-analysis is shown in Figure 4. Clearly, there was heterogeneity (I =97%) among
studies; therefore, these results warrant deeper inspection and cautious interpretation. The funnel plots of
the results are shown in Figure 5. Each step of our RMA, its output, and its timing are shown in Figure 6,
showing that altogether the RMA process took roughly 30 minutes to complete.
Discussion
Principal Findings
For the RMA, we leveraged the Evid Science clinical outcomes database to find relevant studies, screened
the database for studies focused on hydroxychloroquine and vision issues, and then performed the meta-
2
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analysis computation. Most crucially, the entire process from the search to analysis took less than 30
minutes. Based on results from 11 studies (N=3585), we could expect to see major eye issues 3.4% (95%
CI: 1.11%-9.96%) of the time when using hydroxychloroquine. We note the high heterogeneity across the
studies (I =97%), requiring caution when interpreting these results. Notably, an RMA such as the present
analysis is meant to raise awareness, and should not be treated as a full systematic literature review or
meta-analysis that should strictly guide treatment. The data and results presented herein are current as of
April 11, 2020.
The screening of articles step is one of the key areas of time savings in RMA. Although we described the
various accuracy metrics in Table 1, the AI is also able to surface study characteristics that can be helpful in
screening for meta-analysis as well. For example, Table 3 shows various study characteristics for a few of
the chosen articles, including time period (retrospective or prospective), cohort focus (groups designated
based on different drugs or conditions), study type (trial or observational), and finally methodology
sentences. These characteristics are all generated by the machine, except for the methodology sentences,
which are surfaced from the text automatically (rather than applied as “tags” to an article). In our RMA, we
chose to include as many data points as possible, which perhaps led to our high level of heterogeneity
(although population size differences clearly influence heterogeneity as well), but we could have been more
specific, focusing on certain study characteristics using the values supplied by the AI. For instance, the
methodology sentences include geographic locations, or we could have focused solely on papers that group
patients by drug, rather than condition. For a complete list of characteristics for all articles, refer to
Multimedia Appendix 2.
Limitations
Of course, there are limitations to our approach as well. One important aspect to note is that although RMA
can very rapidly produce answers to clinical questions, nothing (yet) replaces human ingenuity and
creativity (and most importantly, common sense). A major limitation of RMA currently is that the AI is not
sophisticated enough to present more than data and mathematical results; that is, it cannot make meaningful
interpretations.
In this case, for instance, the result is indicative (3.4 events per 100 observations), but the confidence
interval is wide and the I  is high. Therefore, the result of our RMA warrants cautious interpretation. A
machine cannot produce this nuance summary but can only provide the data and results for a person to then
interpret.
Another limitation is that models may make mistakes. Of course, human beings make mistakes as well, but
model mistakes can be counterintuitive. For instance, in this study, one of the results extracted was that all
cases had documented blindness associated with something other than hydroxychloroquine. This implies
zero cases for hydroxychloroquine, but the machine did not pick up on this. It is obvious to us as humans
that the inverse result is what we want, but that is a common sense observation. Therefore, there is a
tradeoff between assuming there will be some mistakes and the rapid nature of RMA. We note that there
are often mistakes in human analysis as well.
A final limitation is acceptability. We introduce RMA as a means to more rapidly produce evidence that can
be helpful in clinical decision making. However, without trust in and the adoption of AI-assisted evidence,
such results might exist in a vacuum. If that is the case, clinical practice will not benefit from the
advancement. Therefore, this limitation necessitates that, to be useful, current AI-generated evidence must
be accepted in some manner. We hope that our transparency in this article (presenting results and data)
helps to bring some change in this regard.
2
2
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Conclusion
In this article, we have presented a new framework for answering clinical questions when time is at a
premium and can be traded off for data quality. We call this approach RMA, and we demonstrated its utility
in answering a clinical question about ocular toxicity associated with hydroxychloroquine as a proposed
treatment for COVID-19. By leveraging RMA, in roughly 30 minutes we were able to discern a potential
association with an incidence of 3.4 events per 100 observations (95% CI 1.11-9.96). Although the results
raise further questions that need to be considered (eg, regarding the high heterogeneity), they nevertheless
raise attention to a relevant clinical issue with the drug hydroxychloroquine. Importantly, the whole
assessment was completed in less than 30 minutes, representing huge time savings compared to the months
it takes for traditional meta-analysis conducted by hand.
Abbreviations
AI artificial intelligence
API application programming interface





Labels from dual-annotator labeling of extractions.
Multimedia Appendix 2
The full study characteristics for Table 3.
Footnotes
Conflicts of Interest: MM, TC, MR, ATQY, and SM are all employees, former employees, or board members of Evid
Science.
References
1. Bastian H, Glasziou P, Chalmers I. Seventy-five trials and eleven systematic reviews a day: how will we
ever keep up? PLoS Med. 2010 Sep 21;7(9):e1000326. doi: 10.1371/journal.pmed.1000326.
https://dx.plos.org/10.1371/journal.pmed.1000326. [PMCID: PMC2943439] [PubMed: 20877712]
[CrossRef: 10.1371/journal.pmed.1000326]
2. Sackett D, Straus S, Richardson WS, Rosenberg W, Haynes RB. Evidence-based medicine: how to
practice and teach EBM, 2nd ed. Edinburgh: Churchill Livingstone; 2000.
Artificial Intelligence for Rapid Meta-Analysis: Case Study on Ocul... https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7459430/?report=pr...
7 of 18 9/18/20, 2:07 PM
3. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. 2011.
[2020-04-10]. https://handbook-5-1.cochrane.org/
4. Tsafnat G, Glasziou P, Choong MK, Dunn A, Galgani F, Coiera E. Systematic review automation
technologies. Syst Rev. 2014 Jul 09;3(1):74–74. doi: 10.1186/2046-4053-3-74.
https://systematicreviewsjournal.biomedcentral.com/articles/10.1186/2046-4053-3-74.
[PMCID: PMC4100748] [PubMed: 25005128] [CrossRef: 10.1186/2046-4053-3-74]
5. Shojania KG, Sampson M, Ansari MT, Ji J, Doucette S, Moher D. How quickly do systematic reviews
go out of date? A survival analysis. Ann Intern Med. 2007 Aug 21;147(4):224–233. doi:
10.7326/0003-4819-147-4-200708210-00179. [PubMed: 17638714] [CrossRef:
10.7326/0003-4819-147-4-200708210-00179]
6. Loughlin EH, Rice JB, Wells HS, Rappaport I, Joseph AA. The treatment of Plasmodium falciparum
malaria with a single dose antimalarial; a preliminary report of the use of hydroxychloroquine, 7-chloro-
4(4-(N-ethyl-N-B-hydroxyethylamino)-1-methylbutylamino)-quinoline diphosphate. Antibiot Chemother
(Northfield) 1952 Apr;2(4):171–4. [PubMed: 24541823]
7. Michelson M. Automating Meta-Analyses of Randomized Clinical Trials: A First Look. AAAI Fall
Symposium on Expanding the Boundaries of Health Informatics Using AI (HIAI); 2014; Arlington, VA.
2014. Jan 01,
8. EvidScience. [2020-04-11]. https://www.evidscience.com/
9. Wallace BC, Kuiper J, Sharma A, Zhu MB, Marshall IJ. Extracting PICO Sentences from Clinical Trial
Reports using Supervised Distant Supervision. J Mach Learn Res. 2016;17:132. http://europepmc.org
/abstract/MED/27746703. [PMCID: PMC5065023] [PubMed: 27746703]
10. Scells H, Zuccon G, Koopman B, Deacon A, Azzopardi L, Geva S. Integrating the Framing of Clinical
Questions via PICO into the Retrieval of Medical Literature for Systematic Reviews. ACM on Conference
on Information and Knowledge Management; 2017; Singapore. 2017. Nov 06,
11. Przybyła P, Brockmeier AJ, Kontonatsios G, Le Pogam M, McNaught J, von Elm E, Nolan K,
Ananiadou S. Prioritising references for systematic reviews with RobotAnalyst: A user study. Res Synth
Methods. 2018 Sep 30;9(3):470–488. doi: 10.1002/jrsm.1311. http://europepmc.org/abstract
/MED/29956486. [PMCID: PMC6175382] [PubMed: 29956486] [CrossRef: 10.1002/jrsm.1311]
12. Marshall I, Kuiper J, Banner E, Wallace B. Automating Biomedical Evidence Synthesis:
RobotReviewer. Annual Meeting of the Association of Computational Linguistics, System Demonstrations;
July 30, 2017; Vancouver, Canada. 2017. [PMCID: PMC5662138] [PubMed: 29093610] [CrossRef:
10.18653/v1/p17-4002]
13. scibert. GitHub. [2020-07-30]. https://github.com/allenai/scibert.
14. Michelson M, Ross M, Minton S. AI2 Leveraging machine-assistance to replicate a systematic review.
Value in Health. 2019 May;22:S34. doi: 10.1016/j.jval.2019.04.006. [CrossRef:
10.1016/j.jval.2019.04.006]
15. Mavrikakis I, Sfikakis PP, Mavrikakis E, Rougas K, Nikolaou A, Kostopoulos C, Mavrikakis M. The
incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal.
Ophthalmology. 2003 Jul;110(7):1321–1326. doi: 10.1016/S0161-6420(03)00409-3. [PubMed: 12867385]
[CrossRef: 10.1016/S0161-6420(03)00409-3]
Artificial Intelligence for Rapid Meta-Analysis: Case Study on Ocul... https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7459430/?report=pr...
8 of 18 9/18/20, 2:07 PM
16. Spinelli FR, Moscarelli E, Ceccarelli F, Miranda F, Perricone C, Truglia S, Garufi C, Massaro L,
Morello F, Alessandri C, Valesini G, Conti F. Treating lupus patients with antimalarials: analysis of safety
profile in a single-center cohort. Lupus. 2018 Sep 28;27(10):1616–1623. doi: 10.1177/0961203318781008.
[PubMed: 29954281] [CrossRef: 10.1177/0961203318781008]
17. Navajas EV, Krema H, Hammoudi DS, Lipton JH, Simpson ER, Boyd S, Easterbrook M. Retinal
toxicity of high-dose hydroxychloroquine in patients with chronic graft-versus-host disease. Can J
Ophthalmol. 2015 Dec;50(6):442–450. doi: 10.1016/j.jcjo.2015.08.003. [PubMed: 26651304] [CrossRef:
10.1016/j.jcjo.2015.08.003]
18. Singh D, Muhieddine L, Einstadter D, Ballou S. Incidence of blindness in a population of rheumatic
patients treated with hydroxychloroquine. Rheumatol Adv Pract. 2019;3(1):rkz009–rkz009. doi:
10.1093/rap/rkz009. http://europepmc.org/abstract/MED/31431997. [PMCID: PMC6649895] [PubMed:
31431997] [CrossRef: 10.1093/rap/rkz009]
19. Chiu S, Shaw J, Luong T, Fong D, Modjtahedi B. Coding patterns used by ophthalmologists for
hydroxychloroquine retinal toxicity. Clin Ophthalmol. 2018;12:2261–2265. doi: 10.2147/OPTH.S170789.
[PMCID: PMC6228045] [PubMed: 30464387] [CrossRef: 10.2147/OPTH.S170789]
20. Cabral R, Klumb E, Couto M, Carneiro S. Evaluation of toxic retinopathy caused by antimalarial
medications with spectral domain optical coherence tomography. Arq Bras Oftalmol. 2019;82(1):12–17.
doi: 10.5935/0004-2749.20190002. https://www.scielo.br/scielo.php?script=sci_arttext&
pid=S0004-27492018005004102&lng=en&nrm=iso&tlng=en. [PubMed: 30403262] [CrossRef:
10.5935/0004-2749.20190002]
21. Espandar G, Moghimi J, Ghorbani R, Pourazizi M, Seiri MA, Khosravi S. Retinal Toxicity in Patients
Treated With Hydroxychloroquine: A Cross-Sectional Study. Med Hypothesis Discov Innov Ophthalmol.
2016;5(2):41–46. http://europepmc.org/abstract/MED/28293646. [PMCID: PMC5347188] [PubMed:
28293646]
22. Jover JA, Leon L, Pato E, Loza E, Rosales Z, Matias MA, Mendez-Fernandez R, Díaz-Valle D,
Benitez-Del-Castillo JM, Abasolo L. Long-term use of antimalarial drugs in rheumatic diseases. Clin Exp
Rheumatol. 2012;30(3):380–387. [PubMed: 22339928]
23. Maturi RK, Yu M, Weleber RG. Multifocal electroretinographic evaluation of long-term
hydroxychloroquine users. Arch Ophthalmol. 2004 Jul;122(7):973–981. doi: 10.1001/archopht.122.7.973.
[PubMed: 15249360] [CrossRef: 10.1001/archopht.122.7.973]
24. Tzekov RT, Serrato A, Marmor MF. ERG findings in patients using hydroxychloroquine. Doc
Ophthalmol. 2004 Jan;108(1):87–97. doi: 10.1023/b:doop.0000018410.08802.d3. [PubMed: 15104171]
[CrossRef: 10.1023/b:doop.0000018410.08802.d3]
25. Neubauer AS, Samari-Kermani K, Schaller U, Welge-Lübetaen U, Rudolph G, Berninger T. Detecting
chloroquine retinopathy: electro-oculogram versus colour vision. Br J Ophthalmol. 2003
Jul;87(7):902–908. doi: 10.1136/bjo.87.7.902. http://bjo.bmj.com/cgi/pmidlookup?view=long&
pmid=12812896. [PMCID: PMC1771768] [PubMed: 12812896] [CrossRef: 10.1136/bjo.87.7.902]
Figures and Tables
Artificial Intelligence for Rapid Meta-Analysis: Case Study on Ocul... https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7459430/?report=pr...
9 of 18 9/18/20, 2:07 PM
Figure 1
Open in a separate window
Traditional meta-analysis (simplified, left) vs rapid meta-analysis using artificial intelligence (AI) (right).
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Figure 2
Example of artificial intelligence–generated results from article text.
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Figure 3
Evid Science artificial intelligence architecture. API: application programming interface.
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Table 1
Extraction results based on 100 randomly selected results, dual-screened.
Result extracted Recall Precision Perfect Precision
Numerator (N=42) 92.86% 95.12% 95.12%
Denominator (N=23) 91.30% 91.30% 91.30%
Percent (N=40) 90.00% 94.74% 92.11%
Continuous Value (N=29) 89.66% 92.86% 92.86%
Continuous Unit (N=24) 83.33% 95.24% 90.48%
Intervention (N=85) 84.71% 94.74% 86.84%
Outcome (N=100) 95.00% 97.94% 79.38%
Open in a separate window
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Table 2






2 400 patients who were treated with recommended dosages
of the drug for a mean of 8.7 years
incidence of hydroxychloroquine-related retinopathy
0 526 hydroxychloroquine retinal toxicity was noted during the first 6 years of treatment
46 845 chloroquine, hydroxychloroquine, or both ophthalmological alterations, confirmed by the ophthalmological
3 12 800 mg/day hydroxychloroquine developed retinal toxicity with scotomas in the Amsler grid and H
automated perimetry, as well as abnormal multifocal electroretin
0 11 long-term hydroxychloroquine documented blindness, in all cases attributed to a cause other tha
hydroxychloroquine-related ocular toxicity
35 678 hydroxychloroquine had hydroxychloroquine toxicity
1 121 hydroxychloroquine prevalence of toxic retinopathy
18 59 hydroxychloroquine retinal toxicity was detected
9 778 antimalarial drugs suffered definite presence of antimalarial retinopathy
11 36 hydroxychloroquine had abnormal response densities in one or both eyes
3 26 hydroxychloroquine results from electrophysiological and clinical evaluation, toxicity
maculopathy)
4 93 chloroquine and hydroxychloroquine therapy developed typical bull’s eye maculopathy
Open in a separate window
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Figure 4
Forest plot for our rapid meta-analysis.
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Figure 5
Funnel plot for our rapid meta-analysisis.
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Figure 6
Overview of the rapid meta-analysis for ocular toxicity associated with hydroxychloroquine.
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Table 3
Study characteristics, pulled via artificial intelligence (see Multimedia Appendix 2 for the
characteristics of all papers).
Methodology Sentences
The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal. To define the risk of
hydroxychloroquine (HCQ)-related retinal toxicity in patients with rheumatoid arthritis (rheumatoid arthritis) and systemic
lupus erythematosus (systemic lupus erythematosus) who are receiving recommended dosages of the drug (< or =6.5
mg/kg/day). Prospective cohort study, from 1985 to 2000. Greek patients with rheumatoid arthritis (n=335) and systemic
lupus erythematosus (n=191) treated with hydroxychloroquine, 400 of whom had completed at least 6 years of treatment.
Treating lupus patients with antimalarials: analysis of safety profile in a single-center cohort. This longitudinal retrospective
study aims at describing the safety profile and the reasons for discontinuation of antimalarials in patients with systemic
lupus erythematosus (systemic lupus erythematosus) and discoid lupus erythematosus (discoid lupus erythematosus),
focusing on ocular toxicity. We analyzed the clinical data of 845 systemic lupus erythematosus and discoid lupus
erythematosus patients; 59% of them were taking antimalarials: 1.4% chloroquine (chloroquine), 88.5%
hydroxychloroquine (hydroxychloroquine) and 10.1% both.
Retinal toxicity of high-dose hydroxychloroquine in patients with chronic graft-versus-host disease. To evaluate retinal
toxicity in patients treated with high-dose hydroxychloroquine (hydroxychloroquine) (Plaquenil, Sanofi Pharmaceuticals)
for chronic graft-versus-host disease (graft versus host disease). Twelve patients with chronic graft versus host disease
treated with 800 mg/day hydroxychloroquine between June 2005 and December 2010.
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